Naveen S. Vasudev, PhD, MBChB, on RCC: Changing the Dosing Schedule of Ipilimumab Plus Nivolumab

September 21, 2021 By The ASCO Post Staff

Naveen S. Vasudev, PhD, MBChB, of the University of Leeds, discusses phase II results from the PRISM trial, which showed that giving ipilimumab every 12 weeks instead of every 3 weeks, in combination with nivolumab, led to lower rates of grade 3 and 4 toxicities in patients with advanced renal cell carcinoma. Efficacy appeared to be comparable between both arms (Abstract LBA29).

Related Content